A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease

Last updated:
2026-07-18
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER, PHASE III STUDY TO ASSESS THE EFFICACY OF BUDESONIDE, GLYCOPYRRONIUM, AND FORMOTEROL FUMARATE METERED DOSE INHALER RELATIVE TO GLYCOPYRRONIUM AND FORMOTEROL FUMARATE MDI ON CARDIOPULMONARY OUTCOMES IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE (THARROS)

Intervention/treatment:
BUDESONIDE-GLYCOPYRRONIUM-FORMOTEROL
Medical condition:
CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
Protocol code:
D5989C00001
Control number:
281222
Status:
Recruiting
Approved:
December 13, 2023
Trial phase:
Phase 3
For more information:
ClinicalTrials.gov - NCT06283966
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
40 Years to 80 Years
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
AstraZeneca Clinical Study Information Center
Role
CONTACT
Phone:
1-877-240-9479
Sponsor
ASTRAZENECA CANADA INC

Locations

Alberta

Research Site
Calgary, Alberta, T3R 1W7
Recruiting
Research Site
Sherwood Park, Alberta, T8L 0N2
Recruiting

British Columbia

Research Site
Kelowna, British Columbia, V1Y 1Z9
Recruiting
Research Site
Richmond, British Columbia, V6V 2L1
Recruiting

Manitoba

Research Site
Winnipeg, Manitoba, R3L 1Z5
Recruiting

Nova Scotia

Research Site
Sydney, Nova Scotia, B1M 0A1
Recruiting

Ontario

Research Site
Ajax, Ontario, L1S 2J5
Recruiting
Research Site
Guelph, Ontario, N1H 1B1
Recruiting
Research Site
Hamilton, Ontario, L8L 5G4
Recruiting
Research Site
Kingston, Ontario, K7L 2V7
Recruiting
Research Site
Kingston, Ontario, K7M 4E7
Recruiting
Research Site
Thunder Bay, Ontario, P7B 7C7
Recruiting
Research Site
Toronto, Ontario, M5T 3A9
WITHDRAWN

Quebec

Research Site
Montreal, Quebec, H4A 3J1
Recruiting
Research Site
Quebec, Quebec, G1G 5X1
Recruiting
Research Site
Quebec, Quebec, G1V 4G5
Recruiting
Research Site
Quebec, Quebec, G1W 4R4
Recruiting
Research Site
Quebec, Quebec, G3K 2P8
COMPLETED
Research Site
Saint-Charles-Borromee, Quebec, J6E 2B4
Recruiting
Research Site
Trois Rivieres, Quebec, G8T 7A1
Recruiting
Research Site
Trois Rivieres, Quebec, G9A 4P3
Recruiting

Saskatchewan

Research Site
Saskatoon, Saskatchewan, S7N 0W8
WITHDRAWN
Did you find what you were looking for?